RUBCN Gene Salih Ataxia Genetic Test in UAE

Executive Summary & Core Metrics

This next‑generation sequencing (NGS) test delivers 99.9% diagnostic sensitivity for detecting pathogenic variants in the RUBCN gene, enabling precise diagnosis and carrier identification for Salih ataxia — a rare autosomal recessive cerebellar ataxia. All processing follows ISO 9001:2015 certified protocols within DNA Labs UAE, a DHA‑licensed facility.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Post‑test telephonic result interpretation with DHA‑licensed genetics specialists.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The RUBCN Gene Salih Ataxia Genetic Test uses next‑generation sequencing to analyse the entire coding region and splice sites of the RUBCN gene, identifying pathogenic variants responsible for this rare autosomal recessive neurological disorder. NGS offers superior analytical sensitivity over traditional single‑gene Sanger sequencing, particularly for deep intronic and regulatory region variants.

Feature	Our Test (NGS – RUBCN Gene)	Closest Alternative (Single‑Gene Sanger)
Precision	Full gene coverage with 99.9% analytical sensitivity	Targeted exon analysis, lower detection of deep intronic/regulatory variants
Methodology	NGS (Next‑Generation Sequencing) – high throughput, simultaneous analysis of all exons and splice sites	Sanger sequencing – sequential reading of individual fragments
Turnaround Time	3–4 Weeks	6–8 Weeks (often batched)
Sample Types	Blood, Extracted DNA, or One‑drop Blood on FTA Card	Typically requires high‑quality blood/DNA, FTA often not accepted

Physician Insight & Safety Protocols

“As a DHA‑licensed consultant in medical genetics, I emphasize that a positive genetic finding must be correlated with the clinical phenotype and family history; a negative result does not exclude a diagnosis when clinical suspicion remains high. Salih ataxia requires careful differentiation from other hereditary ataxias, and I strongly advise discussing all results with a specialised neurologist to fully understand the implications for the patient and their family.”

– Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403

Patient Advisory & Medication Safety

Important Medication & Clinical Guidance

Do not discontinue or alter any prescribed medication without consulting your treating physician. This genetic test is a diagnostic aid and does not replace a comprehensive neurological evaluation or emergency medical care.

Exclusion Criteria & Emergency Red Flags

Severe cognitive impairment or inability to provide informed consent (requires legal guardian).
Active febrile illness or acute neurological decompensation – postpone testing until clinically stable.
Minors must be accompanied by a parent or legal guardian, and a paediatric neurologist consultation is mandatory under UAE regulations.
ER Red Flags: Sudden loss of consciousness, new‑onset seizures, or rapid progression of ataxia warrant immediate emergency care — do not delay treatment for genetic testing.

Patient FAQ & Clinical Guidance

1. What is the RUBCN Gene Salih Ataxia Genetic Test?

The RUBCN gene test identifies mutations causing Salih ataxia, a rare autosomal recessive neurological disorder. It is essential for accurate diagnosis, carrier detection, and informed family planning. The test examines the entire coding region and splice sites of the RUBCN gene using next‑generation sequencing, providing significantly higher sensitivity than traditional Sanger sequencing.

2. How is the test performed and what sample is required?

A certified phlebotomist collects a simple blood sample, extracted DNA, or a single drop on an FTA card during our ISO‑certified mobile home collection service (available daily 8 AM to 11 PM). No invasive tissue biopsy is required. The cold‑chain transport system preserves specimen integrity from collection to laboratory processing.

3. What is the turnaround time and how are results delivered?

Results are delivered within 3 to 4 weeks from sample receipt. A secure digital report is provided to the ordering physician, and a telephonic consultation with a DHA‑licensed genetics specialist is included to help you understand the clinical implications of your results.

4. Are my results confidential under UAE law?

Yes. All genetic data is handled in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Access to your results is restricted solely to the ordering physician and authorised individuals only after obtaining your explicit written consent.

UAE Regulatory & Data Privacy Adherence

Comprehensive Legal & Privacy Compliance

Data Protection: Fully compliant with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL).
Health Data Governance: Adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Medical Liability & Patient Safety: All clinical procedures follow the standards set by Federal Decree‑Law No. 4 of 2016 on Medical Liability.
DHA Licensing: DNA Labs UAE operates under DHA Facility License Number 1143, ensuring full regulatory oversight by the Dubai Health Authority.
Quality Certification: ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).

Clinical & Logistical Metadata

Test Name	RUBCN Gene Salih Ataxia Genetic Test (NGS)
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Peripheral Whole Blood, Extracted DNA, or One‑drop Blood on FTA Card – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection Available Daily 8 AM–11 PM
Methodology Used	Next‑Generation Sequencing (NGS) – Full gene coverage of all exons and splice sites
ICD-10-CM Code	G11.0 – Congenital nonprogressive ataxia
LOINC Code	94222-2 – RUBCN gene mutation analysis in Blood or Tissue by Molecular genetics method
DHA Facility License & Laboratory Address	DHA Facility License Number: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE